Cormedix (CRMD)
NASDAQ:CRMD
CRMD Stock Chart & Stats
$6.70
$0.06(0.58%)
At close: 4:00 PM EST
$6.70
$0.06(0.58%)
Day’s Range― - ―
52-Week Range$5.60 - $17.43
Previous CloseN/A
Volume1.29M
Average Volume (3M)1.57M
Market Cap
$529.64M
Enterprise Value$532.73M
Total Cash (Recent Filing)$149.52M
Total Debt (Recent Filing)$148.91M
Price to Earnings (P/E)5.1
Beta1.53
Next Earnings
May 07, 2026EPS Estimate
0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding79,050,390
10 Day Avg. Volume1,457,037
30 Day Avg. Volume1,565,056
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.07
Price to Sales (P/S)2.69
P/FCF Ratio4.85
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue1.71
Enterprise Value/Gross Profit1.93
Enterprise Value/Ebitda3.23
Forecast
1Y Price Target
$13.25Price Target Upside97.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.92
Revenue Forecast (FY)$306.52M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutsAnalyst highlights the upcoming late-stage Rezzayo prophylaxis trial readout as a potential major catalyst that could validate efficacy and enable multiple commercial use cases.
Financial FlexibilityStrong cash and short-term investments combined with an authorized share repurchase provide financial flexibility to support operations and pursue growth while awaiting clinical catalysts.
Pipeline OptionalityAnalyst notes the current valuation excludes potential contributions from Rezzayo and Talphera, creating upside optionality if clinical programs post favorable results.
Bears Say
Expense And Model PressureReported GAAP expenses exceeded expectations and modest model revisions, including higher operating costs, led analysts to trim valuation targets.
Reimbursement TransitionAnalyst warns the TDAPA reimbursement transition is expected to reduce DefenCath net pricing and create a material near-term revenue headwind.
Revenue Guidance And Investor ExpectationsCompany revenue guidance and preliminary sales results fell short of analyst expectations, prompting investor disappointment and downward pressure on the stock.
Cormedix News
CRMD FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was $5.60 and its highest was $17.43 in the past 12 months.
What is Cormedix’s market cap?
Cormedix’s market cap is $529.64M.
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is May 07, 2026 which is in 41 days.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Mar 05, 2026. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.816 by -$0.656.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is 0.47.
How many shares outstanding does Cormedix have?
Cormedix has 79,050,390 shares outstanding.
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of $0.16 in its last earnings report, missing expectations of $0.816. Following the earnings report the stock price went down -11.517%.
Which hedge fund is a major shareholder of Cormedix?
Currently, no hedge funds are holding shares in CRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cormedix Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.25 (97.76% Upside)
$13.25 (97.76% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $328.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.94%
12-Months-Change
Fundamentals
Return on Equity
58.50%
Trailing 12-Months
Asset Growth
638.46%
Trailing 12-Months
Company Description
Cormedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CRMD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced several strong operational and financial achievements — including the Melinta acquisition, realization of $35M synergies, robust pro forma revenue ($401.3M), healthy cash (~$148.5M) and a clear pipeline catalyst with RIZEAO top-line data expected in Q2 2026 — against meaningful near-term headwinds tied to the TDAPA-to-bundle reimbursement transition, expected price erosion for DEFENCATH, customer concentration risk, and materially higher operating expenses following the merger. Management offered conservative guidance that reflects those reimbursement risks while preserving upside potential from Medicare Advantage contracting, inpatient adoption, and RIZEAO/TPN development programs. On balance, the positives around completed integration, liquidity, and upcoming clinical catalysts are offset by significant reimbursement and concentration risks that could materially pressure DEFENCATH revenue absent favorable contracting or legislative outcomes.View all CRMD earnings summariesCRMD Stock 12 Month Forecast
Average Price Target
$13.25
▲(97.76% Upside)
Technical Analysis
Arbutus Biopharma
―
Immatics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Zenas BioPharma, Inc.
―
Ownership Overview
2.89% Insiders
8.55% Mutual Funds
16.98% Other Institutional Investors
59.63% Public Companies and Individual Investors